Back to top
more

Intellia Therapeutics (NTLA)

(Delayed Data from NSDQ)

$12.62 USD

12.62
14,215,659

+0.36 (2.89%)

Updated Oct 31, 2025 04:00 PM ET

After-Market: $12.73 +0.11 (0.87%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.16%
3Hold10.10%
4Sell5.63%
5Strong Sell2.84%
S&P50011.45%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (94 out of 243)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues

by Zacks Equity Research

Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of +983.33% and +20.88%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Kanishka Das headshot

Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?

by Kanishka Das

Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus

by Abhinab Dasgupta

Zacks' winning streak continues as UnitedHealth, Ovid and Micron deliver standout gains across key model portfolios.

Zacks Equity Research

Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 63.7% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus

by Santanu Roy

Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: LendingTree, AutoZone, J&J in Focus

by Abhinab Dasgupta

Zacks highlights winners like LendingTree, AutoZone, and Johnson & Johnson as its proven stock-picking strategies continue to shine.

Zacks Equity Research

NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up

by Zacks Equity Research

Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.

Zacks Equity Research

Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?

by Zacks Equity Research

Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?

by Zacks Equity Research

Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus

by Abhinab Dasgupta

Even in a choppy market, Zacks' strategies are spotlighting winners like Oracle, Intellia, and Pharming Group, proving the value of a disciplined, research-driven approach.

Kanishka Das headshot

Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?

by Kanishka Das

CRISPR Therapeutics pushes beyond Casgevy with in vivo programs like CTX310, CTX320 and plans for two more studies by 2025-end.

Kanishka Das headshot

CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock

by Kanishka Das

CRSP surges 41.4% in three months, fueled by promising CTX310 study data and accelerating Casgevy sales.

Zacks Equity Research

Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?

by Zacks Equity Research

CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus

by Santanu Roy

Zacks spotlights Digi Power X, RF Industries and Starbucks as standout gainers amid market volatility and economic uncertainty.

Zacks Equity Research

Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

by Zacks Equity Research

NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +3.88% and +9.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock

by Ahan Chakraborty

BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.

Ekta Bagri headshot

3 Genomics Stocks Worth Adding to Your Portfolio in 2025

by Ekta Bagri

CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus

by Santanu Roy

AU, CAT and HSY are standing out as Zacks' high-conviction picks, with each posting double-digit gains in recent weeks.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus

by Abhinab Dasgupta

Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears.